We are pleased to announce that Chemestmed has secured a grant of approximately €2 million from the Estonian Business and Innovation Agency for the project titled “Preclinical development of novel first-in-class epitranscriptomic drug candidates against neuropsychiatric disorders”. Combined with Chemestmed’s own contribution, the project budget totals €2.9 million. This funding will support the completion of IND-enabling studies required to move our novel molecule into clinical trials as a potential treatment for conditions such as anxiety and Parkinson’s disease.
We’re excited to share our latest profile article published in Nature Biopharma Dealmakers, highlighting our pioneering work with small-molecule activators (restoratives) of RNA methylation. This publication provides a compact overview of our developments in leveraging m6A restoration for treating neurodegenerative, neuropsychiatric, and metabolic disorders, including Parkinson’s disease, anxiety, and type 2 diabetes.
The Chemestmed team is back in Tartu after four days filled with exciting science and inspiring discussions at BIO-Europe’s 30th anniversary event!
Professor Jaanus Harro and his research team have recently published an important study in Acta Neuropsychiatrica showcasing the effects of METTL3/METTL14 activators on anxiety-related behaviours.
Chemestmed is attending BIOEurope! Join us in Stockholm, Sweden, from November 4–6, 2024, to celebrate the event's 30th anniversary. Meet our team Dr. Sigrid Selberg, Prof. Mati Karelson and Prof. Jaanus Harro.
Chemestmed was thrilled to participate in the BIO International Convention in San Diego from June 3-6.
